Preface US Renal Data System 2013 Annual Data Report Allan J. Collins, MD, Robert N. Foley, MB, Blanche Chavers, MD, David Gilbertson, PhD, Charles Herzog, MD, Areef Ishani, MD, Kirsten Johansen, MD, Bertram L. Kasiske, MD, Nancy Kutner, PhD, Jiannong Liu, PhD, Wendy St. Peter, PharmD, MS, Haifeng Guo, MS, Yan Hu, MS, Allyson Kats, MS, Shuling Li, PhD, Suying Li, PhD, Julia Maloney, MS, Tricia Roberts, MS, Melissa Skeans, MS, Jon Snyder, PhD, Craig Solid, PhD, Bryn Thompson, BA, Eric Weinhandl, MS, Hui Xiong, MS, Akeem Yusuf, PhD, David Zaun, MS, Cheryl Arko, BA, Shu-Cheng Chen, MS, MPH, Frank Daniels, BS, James Ebben, BS, Eric Frazier, BS, Roger Johnson, Daniel Sheets, BS, Xinyue Wang, BA/BS, Beth Forrest, BBA, Delaney Berrini, BS, Edward Constantini, MA, Susan Everson, PhD, Paul Eggers, PhD, and Lawrence Agodoa, MD

T

his 25th US Renal Data System (USRDS) Annual Data Report contains data through 2011, and again examines chronic kidney disease (CKD) in the United States, characterizing its burden in the general population. In the first section, we offer important data on the impact of CKD, and use the CKD staging system as a predictor of morbidity and mortality. We also compare hospitalization and rehospitalization rates and evaluate adverse events and interventions associated with cardiovascular disease. And we continue to report Medicare Part D prescription drug use, acute kidney injury (AKI), and costs associated with CKD. The second section focuses on end-stage renal disease (ESRD). At the end of 2011, 615,899 dialysis and transplant patients were receiving treatment for ESRD—a 3.2% increase from 2010. There were 115,643 new cases of ESRD reported; this was a 1.5% decrease from 2010 and the first decline in actual counts of new ESRD patients over the last 30 years. Total Medicare costs rose 5% in 2011, to $549 billion, while costs for ESRD reached $34.3 billion, accounting for 6.3% of the Medicare budget and an increase of 5.4% from 2010. Data now show similar reductions in mortality rates among patients of all vintages, and there is continued progress in the first year of hemodialysis therapy. Expanded data on

Am J Kidney Dis. 2014;63(1)(suppl 1):evii

rehospitalization after a prior discharge show that 36% of hemodialysis patients are rehospitalized within 30 days of discharge, a number substantially higher than rates found in the general Medicare and CKD populations. Of particular concern are rates of hospitalization for infection in the hemodialysis population, which have increased 43% since 1993. We continue our evaluation of major changes occurring after the start of the bundled Prospective Payment System in January 2011, looking at providers switching to the new system, at pre- and post-bundle changes in the use of erythropoietin, intravenous iron, and vitamin D, and at changes in hemoglobin levels and trends in transfusion events.

ACKNOWLEDGEMENTS Support: Funding for the USRDS Coordinating Center is provided under contract to the Minneapolis Medical Research Foundation (MMRF; NIH contract HHSN 267 2007 15002C/ NO1-DK-7-5002). Financial Disclosure: Relevant financial interests for contributors to the supplement are listed on page e4.

Ó 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. 0272-6386/$36.00 http://dx.doi.org/10.1053/j.ajkd.2013.11.001

evii

US Renal Data System 2013 Annual Data Report.

US Renal Data System 2013 Annual Data Report. - PDF Download Free
54KB Sizes 0 Downloads 0 Views